Royal Bank Of Canada Issues Pessimistic Forecast for Nuvation Bio (NYSE:NUVB) Stock Price

Nuvation Bio (NYSE:NUVB) had its target price lowered by equities research analysts at Royal Bank Of Canada from $20.00 to $17.00 in a research report issued on Thursday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Royal Bank Of Canada‘s price objective would indicate a potential upside of 308.65% from the stock’s current price.

Several other equities analysts also recently weighed in on the company. Wall Street Zen downgraded Nuvation Bio from a “hold” rating to a “sell” rating in a research report on Saturday, October 10th. B. Riley Financial restated a “buy” rating on shares of Nuvation Bio in a research report on Friday, August 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nuvation Bio in a research report on Thursday, October 15th. HC Wainwright increased their target price on shares of Nuvation Bio from $17.00 to $21.00 and gave the company a “buy” rating in a research note on Monday, July 27th. Finally, Wedbush restated an “outperform” rating and issued a $11.00 target price on shares of Nuvation Bio in a report on Wednesday, September 16th. Nine analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $12.89.

Nuvation Bio Price Performance

Shares of NYSE NUVB traded down $0.03 during mid-day trading on Thursday, hitting $4.16. 5,334,790 shares of the company’s stock traded hands, compared to its average volume of 5,100,673. The company has a debt-to-equity ratio of 0.96, a current ratio of 8.37 and a quick ratio of 8.14. Nuvation Bio has a 1 year low of $3.97 and a 1 year high of $9.75. The company’s 50-day moving average is $5.39 and its two-hundred day moving average is $5.37. The company has a market capitalization of $1.46 billion, a P/E ratio of -10.40 and a beta of 1.73.

Nuvation Bio (NYSE:NUVB) last released its quarterly earnings results on Wednesday, November 4th. The company reported ($0.12) EPS for the quarter, hitting the consensus estimate of ($0.12). Nuvation Bio had a negative return on equity of 46.59% and a negative net margin of 88.18%. The company had revenue of $44.95 million during the quarter, compared to analyst estimates of $34.39 million. On average, equities analysts anticipate that Nuvation Bio will post -0.34 EPS for the current fiscal year.

Insider Buying and Selling at Nuvation Bio

In related news, insider Gary Hattersley sold 100,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $7.09, for a total transaction of $709,000.00. Following the completion of the sale, the insider directly owned 100,000 shares of the company’s stock, valued at approximately $709,000. This trade represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 30.11% of the company’s stock.

Hedge Funds Weigh In On Nuvation Bio

Several hedge funds have recently bought and sold shares of NUVB. ACT Capital Partners L.P. purchased a new stake in shares of Nuvation Bio during the third quarter valued at $3,245,000. Alps Advisors Inc. increased its stake in Nuvation Bio by 32.2% in the 3rd quarter. Alps Advisors Inc. now owns 465,179 shares of the company’s stock worth $2,605,000 after buying an additional 113,184 shares during the period. Torray Investment Partners LLC purchased a new position in Nuvation Bio in the 3rd quarter worth about $1,539,000. Profund Advisors LLC lifted its holdings in Nuvation Bio by 297.6% during the 3rd quarter. Profund Advisors LLC now owns 240,483 shares of the company’s stock valued at $1,347,000 after buying an additional 179,994 shares in the last quarter. Finally, Sterling Capital Management LLC lifted its holdings in Nuvation Bio by 847.9% during the 3rd quarter. Sterling Capital Management LLC now owns 8,389 shares of the company’s stock valued at $47,000 after buying an additional 7,504 shares in the last quarter. Institutional investors own 61.67% of the company’s stock.

Key Headlines Impacting Nuvation Bio

Here are the key news stories impacting Nuvation Bio this week:

• Positive Sentiment: IBTROZI revenue grew 18% sequentially. Management also outlined the possibility of European approval in the first half of 2027, which could trigger an approximately $30 million milestone payment. Article: Nuvation Bio outlines potential Europe approval and IBTROZI growth
• Positive Sentiment: Nuvation Bio reported a third-quarter loss of $0.12 per share, while revenue of $44.95 million exceeded analyst estimates cited in the company’s earnings coverage. The loss was narrower than a year earlier. Article: Nuvation Bio reports Q3 loss and revenue
• Neutral Sentiment: H.C. Wainwright reiterated its Buy rating and $21 price target, although it trimmed its Q1 2027 EPS estimate to break-even from $0.01. Article: Nuvation Bio gets a Buy from H.C. Wainwright
• Neutral Sentiment: RBC lowered its price target from $20 to $17 but maintained an Outperform rating. B. Riley also reduced its target, from $14 to $13, while keeping its Buy rating. The lower targets are a cautionary note, though both firms remain positive on the shares. Article: B. Riley adjusts Nuvation Bio price target

Nuvation Bio Company Profile

Nuvation Bio, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with cancer. The company seeks to address areas of significant unmet need, with an emphasis on targeted therapies for solid tumors.

Nuvation Bio’s lead product is taletrectinib, a next-generation tyrosine kinase inhibitor designed for patients with ROS1-positive non-small cell lung cancer (NSCLC), including certain tumors that have developed resistance to earlier ROS1-targeted treatments.